Final results from the Phase III ASPIRE study were published by Amgen showing that carfilzomib (Kyprolis®) when used with lenalidomide and dexamethasone reduced the risk of death by 21 percent compared to len/dex doublet alone. Median overall survival for carfilzomib-lenalidomide-dex wss 48.3 months vs. lenalidomide-dex at 40.4 months.
“For multiple myeloma patients, the first relapse is usually the most devastating,” said David S. Siegel, M.D., Ph.D., chief of the Division of Multiple Myeloma at John Theurer Cancer Center in Hackensack, N.J., and investigator on the ASPIRE trial. “These data clearly show that the addition of KYPROLIS – for just 18 cycles – to lenalidomide and dexamethasone at relapse gave patients a significantly improved chance of survival. With these results, this KYPROLIS regimen should be considered a new standard of care.”
Kyprolis is currently approved in the U.S. for the following:
- In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
- As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
The recent study results are being submitted to a medical conference (most likely the ASH conference) where the data will be presented in more detail.